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CC BY-NC-ND license (http://creativeBackground: To determine whether the presence of a capsule regulator gene [i.e., regulator of
mucoid phenotype A (rmpA) gene] contributes to virulence on extended-spectrum b-lacta-
mase-producing Klebsiella pneumoniae (ESBL-KP) with serotype non-K1/K2 strains.
Methods: Twenty-eight ESBL-KP and non-ESBL-KP isolates were collected from the Tri-Service
General Hospital (Taipei, Taiwan). The impact of the virulent rmpA gene in different capsular
polysaccharide serotypes on ESBL-KP and non-ESBL-KP isolates was studied by a neutrophil
phagocytosis reaction, a serum bactericidal assay, and an animal survival model.
Results: Resistance to broad spectrum antibiotics was more prevalent in ESBL-KP strains than
in non-ESBL-KP strains (p < 0.01). The ESBL-KP strains had different molecular patterns from
non-ESBL-KP strains, based on pulsed-field gel electrophoresis. The frequency of serum-
resistant isolates was the highest among ESBL-KP strains with rmpA (i.e., rmpAþ) [71.4%
(5/7)] than among of non-ESBL-KP rmpAþ strains [42.8% (6/14)], ESBL-KP strains without rmpA
(rmpA) [33.3% (7/21)], and non-ESBL-KP rmpA strains [14.2% (2/14)]. The most significant
increase in neutrophil resistance occurred in the ESBL-KP rmpAþ strains in comparison toInfectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General
Road, Neihu 114, Taipei, Taiwan.
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RmpA gene increases ESBL-K. pneumoniae virulence 495the non-ESBL-KP rmpAþ, ESBL-KP rmpA, and non-ESBL-KP rmpA strains (p < 0.01). The re-
sults of the animal survival model were compatible with the neutrophil phagocytosis reaction
and serum bactericidal assay.
Conclusion: We conclude that the pathogenic potential is greater in rmpAþ ESBL-KP strains
than in rmpAe ESBL-KP and non-ESBL-KP strains.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
In recent decades, the incidence of extended-spectrum b-
lactamase-producing Klebsiella pneumoniae (ESBL-KP) in
patients with nosocomial infections has increased.1e5 The
coexistence with other resistant mechanisms has made this
opportunistic pathogen more difficult to treat because
effective antibiotic options are limited.6e8 Carbapenem is
not yet very effective for ESBL-KP, although in recent years
increasing reports of carbapenem resistance have been of
great concern.8e10 Furthermore, ESBL-KP is reportedly
more virulent than non-ESBL-KP. Increased serum resis-
tance and impairment of the respiratory burst within neu-
trophils have been documented in ESBL-KP and non-ESBL-
KP strains.11,12
Different virulence factors such as lipopolysaccharides
(O-antigen), capsular polysaccharides (K-antigen), fimbrae,
and siderophores have been reported in K. pneumoniae.13
In addition, different genes related to virulence have also
been documented. Serotypes K1 and K2 are the most viru-
lent types of K. pneumoniae in community-acquired in-
fections and in animal studies.14e16 The antiphagocytic
properties of serotypes K1 and K2 may contribute to the
high virulence17; however, serotypes K1 and K2 of
K. pneumoniae are rarely encountered in nosocomial in-
fections.18 The virulence for serotypes non-K1/K2 of
K. pneumoniae has not been reported in nosocomial in-
fections involving ESBL-KP. In addition to capsular serotype
K antigens, a capsule regulator gene [i.e., regulator of
mucoid phenotype (rmpA)] reportedly contributes to
resistance in neutrophil phagocytosis.16,19 Taken together,
additional studies are needed concerning whether rmpA in
strains of ESBL-KP with non-K1/K2 contributes to high
virulence in non-ESBL-KP. In the present study, we
collected 28 nosocomial non-ESBL-KP isolates and ESBL-KP
isolates and studied their virulence, based on the pres-
ence of rmpA in in vitro and in vivo virulence assays.Materials and methods
Collection of ESBL-KP and non-ESBL-KP isolates
K. pneumoniae isolates were collected between January
2008 and June 2009 at the Tri-Service General Hospital
(Taipei, Taiwan) from patients with nosocomial bacter-
emia. The strains of K. pneumoniae bacteremia were
collected from nosocomial bacteremia with ESBL-KP strains
and non-ESBL-KP strains. The criterion for a nosocomialbacteremia was that the strain was isolated from patients
with bacteremia after 48 hours of admission to the hospital.
The ESBL-KP producers were reconfirmed using the disc
diffusion method. The ESBL discs were impregnated with
cefotaxime/clavulanic acid (30 g/10 g) and cefotaxime
(30 g), and ceftazidime/clavulanic acid (30 g/10 g) and
ceftazidime (30 g; Becton Dickinson, Franklin Lakes, NJ,
USA). An increase of 5 mm or greater in the zone diameter
for clavulanic acid-supplemented discs, compared to plain
discs, indicated an ESBL producer.20 In this study, 56 strains
(28 ESBL-KP and 28 non-ESBL-KP strains) were selected
randomly. Serotyping was assessed by the capsular swelling
technique and counter current immunoelectrophoresis.15
The mucoviscosity was assessed using a string test, as
previously reported.15The determined minimal inhibitory concentrations
of different strains of K. pneumonia
Fifty-six different strains of K. pneumoniae were obtained
from patients with bacteremia. The minimal inhibitory
concentrations (MIC) of antimicrobial agents were deter-
mined by the E-test in accordance with the recommenda-
tions from the Clinical and Laboratory Standards Institute
(CLSI; Wayne, PA, USA).21 We determined antimicrobial
susceptibility to ampicillin, amoxicillin/clavulanate,
piperacillin, aztrenam, cefazolin, ceftazidime, cefotaxime,
cefepime, gentamicin, amikacin, ciprofloxacin, and imipe-
nem, based on recommendations of the CLSI.22 The
breakpoint of moxalactam was used for flomoxef.22Pulsed-field gel electrophoresis analysis
Total DNA was prepared and pulsed-field gel electropho-
resis (PFGE) was performed, as previously described.23 The
restriction enzyme XbaI (New England Biolabs, Beverly, MA,
USA) was used at the manufacturer’s suggested tempera-
ture. Restriction fragments were separated by PFGE in 1%
agarose gel (Bio-Rad, Hercules, CA, USA) in 0.5  Tris/
Borate/EDTA (TBE) buffer (45 mM Tris, 45 mM boric acid,
and 1.0 mM EDTA; pH 8.0) for 22 hours at 200 V at a tem-
perature of 14C with ramped times of 2e40 seconds using
the Bio-Rad CHEF MAPPER apparatus (Bio-Rad Laboratories,
Richmond, CA, USA). The gels were then stained with
ethidium bromide and photographed under UV light. The
resulting genomic DNA profiles or “fingerprints” were
interpreted in accordance with established guidelines.24
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polymerase chain reaction
Polymerase chain reaction (PCR) was used to target specific
genes for the ESBL-KP types and rmpA gene. For detecting
the rmpA gene, a primer was designed using previously
published sequences.16,19 An overnight-cultured bacterial
colony was added to 300 mL of water and boiled for 15
minutes to release the DNA template. For detecting the
ESBL-KP genes, conserved primers sets of SHV-type, TEM-
type, and CTX-M-type b-lactamases were selected (Table
1). The PCR products were sequenced to determine the
ESBL-KP types.25e28 A chromosomal 16S rDNA gene was the
internal positive control for each PCR reaction with primers
designed as follows: forward, 50-ATCTGGTGGACTACTCGC-
30; and reverse, 50-GCCTCATTCAGTTCCGTT-30.
The reaction mixture was maintained at 95C for 5 mi-
nutes, followed by 40 temperature cycles of 95C for 1
minute, 50C for 1 minute, 72C for 2 minutes, and 72C for
7 minutes.16,19,25e28
Phagocytosis assay
Neutrophil isolation from healthy volunteers and bacteria
labeling with fluorescein isothiocyanate (FITC) were per-
formed, as previously described.17 A mixture consisting of
labeled bacteria, a neutrophil suspension, pooled normal
human serum, and phosphate buffered saline (PBS; pH, 7.4)
was incubated for reaction of 0 minutes and 10 minutes in a
shaking water bath at 37C. After centrifugation, the su-
pernatant was removed and the cell pellet was resuspended
in an ice-cold PBS solution. Ethidium bromide solution was
added. Fluorescein isothiocyanate fluorescence was detec-
ted using the FACScan scanner (Becton Dickinson Immuno-
cytometry Systems, San Jose, CA, USA). Using a logarithmic
amplifier, fluorescence distribution data were displayed as
single histograms for FL1-H. The mean percentage of neu-
trophils that contained FITC-stained bacteria at 15 minutes
in six repeated results was used as the phagocytosis rate.Table 1 Specific primers used for amplification of the



















rmpA Z regulator of mucoid phenotype A.Serum killing assay
Serum bactericidal activity was measured using a modifi-
cation of the method by Hughes and Podschun.29,30 Bacteria
grown in nutrient broth were collected during the early
logarithmic phase. The viable bacteria concentration was
adjusted to 1  106 colony-forming units (CFU)/mL and
reacted with 75% pooled human sera. A strain was consid-
ered “serum-resistant” or “serum-sensitive” if the grading
was the same in all experiments. Each isolate was classified
as “highly sensitive” (Grade 1 or 2), “intermediately sen-
sitive” (Grade 3 or 4), or “resistant” (Grade 5 or 6). Each
strain was tested at least three times.
Mice lethality study
Pathogen-free male BALB/c mice (age, 6e8 weeks old;
weight, 20e25 g) were obtained from the National Labo-
ratory Animal Center (Taipei, Taiwan). All experiments
involving mice were approved by the Committee on Insti-
tutional Animal Care and Use of the Tri-Service General
Hospital and National Defense Medical Center (Taipei,
Taiwan). Mice were injected intraperitoneally with the
designated strains. The inoculum contained 106 CFU and 107
CFU. Mouse mortality was assessed for up to 14 days. Each
experiment with six mice of each strain was performed
three times and repeated twice.
Statistical analysis
The Student t test was used for statistical analysis. Data are
expressed as the mean  standard deviation (SD). Univari-
ate analyses were performed to compare the differences
between ESBL-KP and non-ESBL-KP in the adjusted serum
resistance and neutrophil killing. Data are expressed as the
least-squares mean  standard error of the mean. The log-
rank test was used for statistical analyses of survival
curves. All statistical tests were two-sided. A p value <0.05
was considered statistically significant.
Results
Serotypes of Klebsiella pneumonia
The serotypes for non-K1/K2 non-ESBL-KP were K16
(nZ 3), K20 (nZ 1), K22 (nZ 2), K28 (nZ 1), K30 (nZ 1),
K38 (n Z 1), K54 (n Z 2), K55 (n Z 4), and non-typed se-
rotypes (n Z 13). The serotypes for non-K1/K2 ESBL-KP
were K6 (nZ 1), K7 (nZ 1), K12 (nZ 1), K15 (nZ 1), K18
(nZ 1), K27 (nZ 1), K35 (nZ 1), K46 (nZ 1), K54 (nZ 1),
K55 (nZ 1), and non-typed serotypes (nZ 18). None of the
enrolled strains exhibited mucovisicosity. Fifty percent (14/
28) of the non-K1/K2 non-ESBL-KP strains had the rmpAþ
gene. Twenty-five percent (7/28) of the non-K1/K2 ESBL-KP
strains had the rmpAþ gene.
Antimicrobial susceptibility of clinical isolates
Twenty-eight non-K1/K2 ESBL-KP strains and 28 non-ESBL-
KP strains were enrolled. They were tested with penicillin,
RmpA gene increases ESBL-K. pneumoniae virulence 497aztreonam, cephalosporin, aminoglycosides, quinolone,
and carbapenem, based on CLSI criteria. The results
showed 100% of the strains had resistance to ampicillin,
piperacillin, cefazolin, cefotaxime, cefepime, and genta-
micin. In the non-K1/K2 ESBL-KP group, the resistance rate
ranged 37.5e68.7% for amoxillin/clavanate, aztreonem,
ceftazidime, amikacin, and ciprofloxacin. In the non-ESBL-
KP group, 100% of the strains showed resistance to ampi-
cillin and 100% of the strains were susceptible to the other
antibiotics (Table 2).
Types of ESBL-KP and PFGE
Fifty-six strains were tested by an ESBL confirmatory assay
and 28 strains were confirmed as ESBL-KP. Twenty-eight
isolates were enrolled and studied for the ESBL-KP types.
Polymerase chain reaction amplification and sequencing of
the PCR products revealed the CTX-M type [100% (28/28)]
existed concomitantly with the SHV-5 type [17.8% (5/28)]
and the SHV-12 type [11% (2/28)]. Three CTX-M types were
identified, among which CTX-M-3 was the most common
ESBL-KP type [92.8% (26/28) of enrolled isolates], followed
by CTX-M-14 and CTX-M-15 [3.5% (1/28) for each]. Molec-
ular typing of ESBL-KP isolates (Fig. 1A) and non-ESBL-KP
isolates (Fig. 1B) confirmed that all strains collected in this
study were unrelated clonally.
Serum resistance in relation to ESBL-KP strains
The results were reproducible in all three experiments for
each strain. The percentage of serum resistance was
significantly higher among the ESBL-KP strains than among
the non-ESBL-KP strains [42.9% (12/28) vs. 28.6% (8/28),
respectively; p Z 0.26]. The percentage of serum resis-
tance was significantly higher among the rmpAþ strains
than among the rmpAe strains [52.4% (11/21) vs. 25.7% (9/
35), respectively; pZ 0.043]. In particular, rmpAþ ESBL-KPTable 2 The minimal inhibitory concentrations of different anti
strains
ESBL-producing K. pneumoniae (n Z
MIC range (mg/L) S (%) I (%)
Ampicillin >16 0 0
Amoxicillin/clavulanate 8 w >16 12.5 25
Piperacillin >64 0 0
Aztreonam 4 w>16 31.25 0
Cefazolin >16 0 0
Ceftazidime 2w>16 12.5 25
Cefotaxime >16 0 0
Flomoxef <2 w >16 75 12.5
Cefepime >16 0 0
Gentamicin >8 0 0
Amikacin <2 w >32 56.25 6.25
Ciprofloxacin <0.03 w >2 50 6.25
Imipenem <0.25 w >8 93.75 0
Minimal inhibitory concentration (MIC) interpretation criteria for anti
Institute criteria were determined, based on the description in Refer
ESBL Z extended-spectrum beta-lactamase; K. pneumoniae Z Klebs
susceptibility; I Z intermediates; R Z resistance.strains [71.4% (5/7)] had the highest serum resistance rate,
compared to the rmpAþ non-ESBL-KP strains [42.8% (6/14)],
the rmpAe ESBL-KP strains [33.3% (7/21)], and the rmpAe
non-ESBL-KP strains [14.2% (2/14)].
Effect of rmpA on neutrophil phagocytosis of ESBL-
KP isolates
Neutrophil phagocytosis of ESBL-KP isolates was signifi-
cantly decreased, compared to that of non-ESBL-KP isolates
(68.45  1.63% and 75.92  1.37%, respectively; pZ 0.001;
Fig. 2A). Neutrophil phagocytosis of rmpAþ K. pneumoniae
was significantly reduced (68.81  1.95%), compared to the
rmpA strains (75.95  0.79%; p Z 0.002; Fig. 2B). The
effect of rmpA gene on phagocytosis was further ascer-
tained. The phagocytosis rate of the four groups (i.e.,
rmpAþ ESBL-KP strains, rmpA ESBP-KP strains, rmpAþ non-
ESBL-KP strains, and rmpA non-ESBP-KP strains) are dis-
played in Fig. 2C. RmpA non-ESBL-KP isolates were all
highly susceptible to neutrophil phagocytosis at 30 minutes
with a phagocytic uptake rate of 80.67  3.63%. No signif-
icant difference was observed in the phagocytic rate of
rmpA ESBL-KP isolates and rmpAþ non-ESBL-KP isolates
(71.16  3.4% vs. 73.35  1.65%, respectively; p Z 0.87;
Fig. 2C). For ESBL isolates, the phagocytosis rate was lower
in the strains with rmpAþ than in the strains with rmpA
(54.14  1.85% vs. 73.35  1.65%, respectively; pZ 0.007).
For the non-ESBL-KP isolates, the phagocytosis rate was
lower in the strains with rmpAþ than in the strains with
rmpA (71.16  3.4% vs. 80.67  3.63%, respectively;
p < 0.001).
Mice lethality study
To further explore the role of the rmpA gene in ESBL-KP
pathogenicity, we examined the different strains of the
rmpAþ/ gene K. pneumoniae in BALB/c mice. The studybiotics in ESBL strains and non-ESBL-producing K. pneumoniae
28) Non-ESBL-producing K. pneumoniae (n Z 28)
R (%) MIC range (mg/L) S (%) I (%) R (%)
100 >16 0 0 100
62.5 <4 100 0 0
100 <2 100 0 0
68.75 <4 100 0 0
100 <2 100 0 0
62.5 <2 100 0 0
100 <2 100 0 0
12.5 <2 100 0 0
100 <0.5 100 0 0
100 <0.16 100 0 0
37.5 <2 100 0 0
43.75 <0.03 100 0 0
6.25 <0.25 100 0 0
microbial agents with/without Clinical and Laboratory Standards
ences 21 and 22.
iella pneumoniae; MIC Z minimal inhibitory concentration; S Z
Figure 1. (A) Molecular typing of 28 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-KP) by pulsed-
field gel electrophoresis (PFGE). (B) Molecular typing of 28 non-ESBL-KP by PFGE. Isolates with 80% similarity (i.e., <3-band
difference) are defined as clonal type strains. A different high genetic polymorphism was observed in each group.
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Figure 2. The graph shows (A) the comparison between
neutrophil phagocytosis of extended-spectrum beta-lactamase
(ESBL)-producing strains (n Z 28) and non-ESBL-producing
strains (n Z 28; p Z 0.001); (B) the comparison between
neutrophil phagocytosis of rmpAþ strains (n Z 21) and rmpAe
strains (n Z 35; p Z 0.002); and (C) the comparison between
neutrophil phagocytosis of rmpAþ/ ESBL-producing and
rmpAþ/ non-ESBL-producing Klebsiella pneumoniae. Resis-
tance is more significant in RmpAþ ESBL-producing strains
(n Z 7) than in rmpAe ESBL-producing strains (n Z 21;
p Z 0.007), rmpAþ non-ESBL-producing strains (n Z 14), and
RmpA gene increases ESBL-K. pneumoniae virulence 499was conducted with different strains selected from the
study groups. The results were similar for several experi-
ments. Each group with 106 CFU (Fig. 3A) and 107 CFU
(Fig. 3B) of one different strains by randomly selection of
rmpAþ ESBL-KP, rmpAþ non-ESBL-KP, rmpA ESBL-KP, and
rmpA non-ESBL-KP was inoculated intraperitoneally into
BALB/c mice. The mice were observed for survival for 14
days (Fig. 3). Mice infected with 106 CFU of rmpAþ strains
of non-ESBL-KP/ESBL-KP had a higher mortality rate
(94.4%/50%), compared to infection by rmpA strains of
non-ESBL-KP/ESBL-KP (94.4%/50% vs. 0%/0%; p < 0.001).
Mice infected with rmpAe ESBL-KP strains and rmpA non-
ESBL-KP strains all survived for 14 days (Fig. 3A). Mice
infected with 107 CFU of rmpAþ ESBL-KP strains had a
higher mortality rate (88.9%) than mice with rmpA ESBL-
KP strains (0%) and rmpA non-ESBL-KP strains (16.6%;
p Z 0.003). No statistically significant differences of mor-
tality rate existed between the rmpA ESBL-KP strains and
the rmpA non-ESBL-KP strains (0% vs. 16.6%, respectively;
p Z 0.6; Fig. 3B). In mice inoculated with 107 CFU of K.
pneumoniae, the survival rates between mice infected
with rmpAþ ESBL-KP strains and mice infected with rmpAþ
non-ESBL-KP strains were the same (88.9% vs. 94.4%,
respectively). In addition, mice infected with ESBL rmpAþ
strains or non-ESBL rmpAþ strains had a lower survival rate
than mice infected with rmpA strains, which suggests that
rmpA contributes to virulence. The study was conducted
with different strains selected from the study groups. The
results were similar for several experiments.Discussion
In this study we investigated the interaction and relation-
ship between ESBL-KP and the rmpA genes of K. pneumo-
niae on serum resistance, neutrophil phagocytosis, and
animals in vivo. The ESBL-KP strains proved to be signifi-
cantly more resistant to serum killing, compared to the
non-ESBL-KP strains. Furthermore, our results showed an
additive effect of the rmpA genes on ESBL-KP in the serum
resistance assay. Based on the neutrophil phagocytosis re-
action, the resistance was greater in rmpAþ ESBL-KP strains
than in rmpAþ non-ESBL-KP strains, rmpA ESBL-KP strains,
and rmpA non-ESBL-KP strains. Invasion of the blood
stream by microorganisms is partly a function of the ability
to evade the bactericidal effect of serum, which is medi-
ated by the complement cascade.31 Because serum and
neutrophil bacteriocidal activities may be innate immunity
factors in host pathogenicity, rmpA genes in ESBL-KP with
superior resistance to serum and neutrophils hypothetically
indicate a greater pathogenic potential in ESBL-KP strains
than in non-ESBL-KP strains of non-K1/K2 K. pneumoniae.
The results in vivo animal experiments were similar to the
bioassay findings.
Virulent factors such as capsular antigens, serum
resistance, and lipopolysaccharides are involved in thermpA non-ESBL-producing strains (n Z 14; p < 0.001). No
statistically significant differences exist between rmpA ESBL-
producing strains and rmpAþ non-ESBL-producing strains
(p Z 0.9).
Figure 3. Lethality in BALB/c mice. Each group of Balb/c mice (for each group, nZ 18) were intraperitoneally inoculated with
(A) 106 colony-forming units (CFU) and (B) 107 CFU of rmpAþ/ extended-spectrum beta-lactamase (ESBL)-producing and rmpAþ/
non-ESBL-producing Klebsiella pneumoniae. Their survival was followed for 14 days. Mice infected with rmpAþ ESBL-producing
strains had the most significant mortality rate, compared to rmpA ESBL-producing strains and rmpA non-ESBL-producing
strains (p Z 0.0003). No statistically significant differences exist between rmpA ESBL-producing strains and rmpA non-ESBL-
producing strains (p Z 0.6; B).
500 H.-A. Lin et al.pathogenicity of K. pneumoniae infections. Among 77
currently recognized capsular serotypes, K1 and K2 are
reportedly associated with virulence and infection. An
epidemiologic study demonstrates that the capsular se-
rotypes K1 and K2 are prevalent in invasive K. pneumoniae
syndrome.28 For K. pneumoniae, some investigations have
shown that lipopolysaccharide molecules determine
serum sensitivity.32e34
According to a previous study, the rmpA gene is
positively associated with the mucoid phenotype in all
strains of K. pneumoniae isolated from invasive liver
abscesses and the bloodstream, regardless of the
capsular serotype.35 The rmpA gene types that harbor
virulent effects on capsular serotypes K1/K2 are un-
known. However, the present study revealed that most
rmpAþ ESBL-KP strains with resistance to innate immu-
nity, including serum killing and neutrophil phagocytosis,
was confirmed by cellular and animal models. Additional
experiments will be needed to clarify whether rmpA gene
types have an effect on capsular serotype K1/K2
infections.
A major limitation of this study was that we did not use
isogenic strains to study the impact of the rmpA gene on
ESBL-KP virulence. The knock-out of the rmpA gene in the
ESBL-KP and complementary experiments need further
demonstration of evidence of this conclusion.
In summary, the expression of the mucoviscosity
phenotype by the presence of the rmpA gene is a generally
virulent factor in infections involving non-K1/K2 ESBL-KP
strain infections. We conclude that the pathogenic poten-
tial is greater in rmpAþ ESBL-KP strains than in rmpA ESBL-
KP strains and non-ESBL-KP strains.
Conflicts of interest
Conflicts of interest: All authors declare no conflicts of
interest.Acknowledgments
This work was supported by grants from National Health
Research Institutes, Medical Foundation in Memory of Dr.
Deh-Lin Cheng, Tri-Service General Hospital, Taipei, Taiwan
(TSGH-C102-123, TSGH-C102-124, DOD103-M078, DOD103-
M079, and DOD103-M080) and National Science Council,
Taipei, Taiwan (NSC101-2314-B-016-022-MY3).References
1. Bush K. Extended-spectrum beta-lactamases in North America,
1987e2006. Clin Microbiol Infect 2008;14(Suppl. 1):134e43.
2. Lytsy B, Sandegren L, Tano E, Torell E, Andersson DI, Melhus A.
The first major extended-spectrum beta-lactamase outbreak in
Scandinavia was caused by clonal spread of a multiresistant
Klebsiella pneumoniae producing CTX-M-15. APMIS 2008;116:
302e8.
3. Liu SW, Chang HJ, Chia JH, Kuo AJ, Wu TL, Lee MH. Outcomes
and characteristics of ertapenem-nonsusceptible Klebsiella
pneumoniae bacteremia at a university hospital in Northern
Taiwan: a matched case-control study. J Microbiol Immunol
Infect 2012;45:113e9.
4. Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F,
et al. Prevalence and spread of extended-spectrum beta-lac-
tamase-producing Enterobacteriaceae in Europe. Clin Micro-
biol Infect 2008;14(Suppl. 1):144e53.
5. Kiratisin P, Chattammanat S, Sa-Nguansai S, Dansubutra B,
Nangpatharapornthawee P, Patthamalai P, et al. A 2-year trend
of extended-spectrum beta-lactamase-producing Escherichia
coli and Klebsiella pneumoniae in Thailand: an alert for
infection control. Trans R Soc Trop Med Hyg 2008;102:460e4.
6. Tseng CP, Wu HS, Wu TH, Lin YT, Fung CP. Clinical character-
istics and outcome of patients with community-onset Klebsi-
ella pneumoniae bacteremia requiring intensive care. J
Microbiol Immunol Infect 2013;46:217e23.
7. Lavilla S, Gonzalez-Lopez JJ, Sabate M, Garcia-Fernandez A,
Larrosa MN, Bartolome RM, et al. Prevalence of qnr genes
among extended-spectrum beta-lactamase-producing
RmpA gene increases ESBL-K. pneumoniae virulence 501enterobacterial isolates in Barcelona, Spain. J Antimicrob
Chemother 2008;61:291e5.
8. Gulmez D, Woodford N, Palepou MF, Mushtaq S, Metan G,
Yakupogullari Y, et al. Carbapenem-resistant Escherichia coli
and Klebsiella pneumoniae isolates from Turkey with OXA-48-
like carbapenemases and outer membrane protein loss. Int J
Antimicrob Agents 2008;31:523e6.
9. Tsui K, Wong SS, Lin LC, Tsai CR, Chen LC, Huang CH. Labora-
tory identification, risk factors, and clinical outcomes of pa-
tients with bacteremia due to Escherichia coli and Klebsiella
pneumonia producing extended-spectrum and AmpC type b-
lactamases. J Microbiol Immunol Infect 2012;45:193e9.
10. Jean SS, Lee WS, Hsueh PR. Nationwide spread of Klebsiella
pneumoniae carbapenemase-2-produing K. pneumoniae
sequence type 11 in Taiwan. J Microbiol Immunol Infect 2013;
46:317e9.
11. Sahly H, Aucken H, Benedi VJ, Forestier C, Fussing V,
Hansen DS, et al. Impairment of respiratory burst in poly-
morphonuclear leukocytes by extended-spectrum beta-lacta-
mase-producing strains of Klebsiella pneumoniae. Eur J Clin
Microbiol Infect Dis 2004;23:20e6.
12. Sahly H, Aucken H, Benedi VJ, Forestier C, Fussing V,
Hansen DS, et al. Increased serum resistance in Klebsiella
pneumoniae strains producing extended-spectrum beta-lacta-
mases. Antimicrob Agents Chemother 2004;48:3477e82.
13. Podschun R, Ullmann U. Klebsiella spp. as nosocomial patho-
gens: epidemiology, taxonomy, typing methods, and pathoge-
nicity factors. Clin Microbiol Rev 1998;11:589e603.
14. Fung CP, Chang FY, Lee SC, Hu BS, Kuo BI, Liu CY, et al. A global
emerging disease of Klebsiella pneumoniae liver abscess: is
serotype K1 an important factor for complicated endoph-
thalmitis? Gut 2002;50:420e4.
15. Lin JC, Siu LK, Fung CP, Tsou HH, Wang JJ, Chen CT, et al.
Impaired phagocytosis of capsular serotypes K1 or K2 Klebsiella
pneumoniae in type 2 diabetes mellitus patients with poor
glycemic control. J Clin Endocrinol Metab 2006;91:3084e7.
16. Yeh KM, Kurup A, Siu LK, Koh YL, Fung CP, Lin JC, et al. Capsular
serotype K1 or K2, rather than magA and rmpA, is a major viru-
lence determinant for Klebsiella pneumoniae liver abscess in
Singapore and Taiwan. J Clin Microbiol 2007;45:466e71.
17. Lin JC, Chang FY, Fung CP, Xu JZ, Cheng HP, Wang JJ, et al. High
prevalence of phagocytic-resistant capsular serotypes of Klebsi-
ellapneumoniae in liver abscess.Microbes Infect2004;6:1191e8.
18. Tsay RW, Siu LK, Fung CP, Chang FY. Characteristics of
bacteremia between community-acquired and nosocomial
Klebsiella pneumoniae infection: risk factor for mortality and
the impact of capsular serotypes as a herald for community-
acquired infection. Arch Intern Med 2002;162:1021e7.
19. Yu WL, Ko WC, Cheng KC, Lee HC, Ke DS, Lee CC, et al. As-
sociation between rmpA and magA genes and clinical syn-
dromes caused by Klebsiella pneumoniae in Taiwan. Clin Infect
Dis 2006;42:1351e8.
20. Queenan AM, Foleno B, Gownley C, Wira E, Bush K. Effects of
inoculum and beta-lactamase activity in AmpC- and extended-
spectrum beta-lactamase (ESBL)-producing Escherichia coli
and Klebsiella pneumoniae clinical isolates tested by using
NCCLS ESBL methodology. J Clin Microbiol 2004;42:269e75.
21. Clinical and Laboratory Standards Institute (CLSI). Perfor-
mance standards for antimicrobial susceptibility testing; 20thinformational supplement M100-S17. Wayne, PA: Clinical and
Laboratory Standards Institute; 2010.
22. Liao CH, Sheng WH, Wang JT, Sun HY, Wang HK, Hsueh PR, et al.
In vitro activities of 16 antimicrobial agents against clinical
isolates of extended-spectrum beta-lactamase-producing
Escherichia coli and Klebsiella pneumoniae in two regional
hospitals in Taiwan. J Microbiol Immunol Infect 2006;39:59e66.
23. D’Agata EM, Gerrits MM, Tang YW, Samore M, Kusters JG.
Comparison of pulsed-field gel electrophoresis and amplified
fragment-length polymorphism for epidemiological in-
vestigations of common nosocomial pathogens. Infect Control
Hosp Epidemiol 2001;22:550e4.
24. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE,
Persing DH, et al. Interpreting chromosomal DNA restriction
patterns produced by pulsed-field gel electrophoresis:
criteria for bacterial strain typing. J Clin Microbiol 1995;33:
2233e9.
25. De CC, Sirot D, Chanal C, Bonnet R, Sirot JA. 1998 survey of
extended-spectrum beta-lactamases in Enterobacteriaceae in
France. The French Study Group. Antimicrob Agents Chemo-
ther 2000;44:3177e9.
26. Fang CT, Lai SY, Yi WC, Hsueh PR, Liu KL, Chang SC. Klebsiella
pneumoniae genotype K1: an emerging pathogen that causes
septic ocular or central nervous system complications from
pyogenic liver abscess. Clin Infect Dis 2007;45:284e93.
27. Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J,
et al. Evolution of extended-spectrum beta-lactam resistance
(SHV-8) in a strain of Escherichia coli duringmultiple episodes of
bacteremia. Antimicrob Agents Chemother 1997;41:647e53.
28. Chang FY, Siu LK, Fung CP, Huang MH, Ho M. Diversity of SHV and
TEM beta-lactamases in Klebsiella pneumoniae: gene evolution
in Northern Taiwan and two novel beta-lactamases, SHV-25 and
SHV-26. Antimicrob Agents Chemother 2001;45:2407e13.
29. Podschun R, Ullmann U. Klebsiella capsular type K7 in relation
to toxicity, susceptibility to phagocytosis and resistance to
serum. J Med Microbiol 1992;36:250e4.
30. Podschun R, Teske E, Ullmann U. Serum resistance properties of
Klebsiella pneumoniae and K. oxytoca isolated from different
sources. Zentralbl Hyg Umweltmed 1991;192:279e85.
31. Olling S. Sensitivity of gram-negative bacilli to the serum bacte-
ricidal activity: a marker of the host-parasite relationship in
acute and persisting infections. Scand J Infect Dis Suppl 1977;10:
1e40.
32. Alberti S, Alvarez D, Merino S, Casado MT, Vivanco F, Tomas JM,
et al. Analysis of complement C3 deposition and degradation
on Klebsiella pneumoniae. Infect Immun 1996;64:4726e32.
33. Kelly RF, Severn WB, Richards JC, Perry MB, MacLean LL,
Tomas JM, et al. Structural variation in the O-specific poly-
saccharides of Klebsiella pneumoniae serotype O1 and O8
lipopolysaccharide: evidence for clonal diversity in rfb genes.
Mol Microbiol 1993;10:615e25.
34. Yeh FC, Yeh KM, Siu LK, Fung CP, Yang YS, Lin JC, et al.
Increasing opsonizing and killing effect of serum from patients
with recurrent K1 Klebsiella pneumoniae liver abscess. J
Microbiol Immunol Infect 2012;45:141e6.
35. Nassif X, Honore N, Vasselon T, Cole ST, Sansonetti PJ. Positive
control of colanic acid synthesis in Escherichia coli by rmpA
and rmpB, two virulence-plasmid genes of Klebsiella pneu-
moniae. Mol Microbiol 1989;3:1349e59.
